Marya Gendzielewski
Endocrinology, Diabetes & Metabolism · Syracuse, NYNPI 1457347924
Payments from drug & device makers
Across 472 payments — averaging $60.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$19K
- Medtronic$2K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Amgen$981
- AstraZeneca$747
- plus $3K from 25 others
What the payments were for
- Speaking & faculty fees$17,12560%
- Travel & lodging$1,5756%
- Food & beverage$9,69834%
- Education$930%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 75 | $19,282 |
| Medtronic(2 entities) | 51 | $2,137 |
| Lilly USA, LLC | 81 | $1,460 |
| Novo Nordisk | 67 | $1,046 |
| Amgen(2 entities) | 37 | $981 |
| AstraZeneca(2 entities) | 28 | $747 |
| Sanofi-aventis U.S. LLC | 31 | $564 |
| Mannkind Corporation | 18 | $408 |
| Boehringer Ingelheim | 10 | $366 |
| Abbott | 7 | $221 |
| Xeris Pharmaceuticals, Inc. | 9 | $202 |
| Radius Health, Inc. | 3 | $152 |
| Corcept Therapeutics | 8 | $146 |
| Insulet Corporation | 7 | $137 |
| Amneal Pharmaceuticals LLC | 4 | $110 |
| Eisai Inc. | 7 | $97 |
| Merck | 6 | $80 |
| Ascensia Diabetes Care US Inc. | 3 | $75 |
| Ultragenyx Pharmaceutical Inc. | 3 | $58 |
| IBSA Pharma Inc. | 3 | $56 |
| Amarin Pharma, Inc. | 3 | $47 |
| Pfizer | 2 | $34 |
| Recordati_rare_diseases_inc. | 1 | $24 |
| Clarus Therapeutics Inc. | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Novartis | 1 | $18 |
| Lifescan, Inc. | 1 | $17 |
| Bayer | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
| Metuchen Pharmaceuticals | 1 | $12 |
| Cequr Corporation | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,550 in reported general payments places this provider in the 85th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 33 | $596 |
| Atorvastatin Calcium | 12 | $74 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $110 | $59633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Syracuse
- Ruth WeinstockSyracuse$3.1M
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Kenneth HershonNew Hyde Park$1.9M
- Michael ShanikSmithtown$1.7M
- Robert SilverBrooklyn$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.